CoChat
Sign Up
Cited by 511RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryExtracellular vesicles in disease

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

The landscape of mRNA nanomedicine

Huang, Xiangang, Kong, Na, Zhang, Xingcai, Cao, Yihai, Langer, Robert, Tao, Wei·2022·Nature Medicine
DOI 10.1038/s41591-022-02061-1
Open this paper in CoChat — free account

Abstract

Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02061-1

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ionizable lipid nanoparticles are an ideal delivery vehicle for nucleic acid therapeutics.

    “Ionizable lipid nanoparticles (LNPs) are an ideal delivery vehicle for nucleic acid therapeutics.19”

    From Predictive High-Throughput Platform for Dual Screening of mRNA Lipid Nanoparticle Blood–Brain Barrier Transfection and Crossing (2024) · cites this paper as [19]

  • Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines and have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results.

    “Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”

    From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [13]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 133

  1. Sharp, P. A. The centrality of RNA. Cell 136, 577–580 (2009). · DOI
  2. Xiao, Y. et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828–3845 (2022). · DOI · Paper page
  3. Emiliano, B. et al. RNA cancer nanomedicine: nanotechnology-mediated RNA therapy. Nanoscale 14, 4448–4455 (2022). · DOI
  4. Langer, R. Controlling the movement of molecules. Q. Rev. Biophys. 52, e5 (2019). · DOI
  5. Karikó, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011). · DOI · Paper page
  6. Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021). · DOI · Paper page
  7. Gupta, A., Andresen, J. L., Manan, R. S. & Langer, R. Nucleic acid delivery for therapeutic applications. Adv. Drug Deliv. Rev. 178, 113834 (2021). · DOI
  8. Granot, Y. & Peer, D. Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—an innate immune system standpoint. Semin. Immunol. 34, 68–77 (2017). · DOI
  9. Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, 1805116 (2019). · DOI
  10. Moffett, H. F. et al. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat. Commun. 8, 389 (2017). · DOI
  11. Islam, M. A. et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2, 850–864 (2018). · DOI · Paper page
  12. Kong, N. et al. Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. Proc. Natl Acad. Sci. USA 119, e2112696119 (2022). · DOI
  13. Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710–728 (2019). · DOI · Paper page
  14. Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. https://doi.org/10.1038/s41565-022-01174-5 (2022). · DOI
  15. Tang, Z. et al. Insights from nanotechnology in COVID-19 treatment. Nano Today 36, 101019 (2021). · DOI
  16. Tang, Z. et al. A materials-science perspective on tackling COVID-19. Nat. Rev. Mater. 5, 847–860 (2020). · DOI
  17. Pardi, N., Muramatsu, H., Weissman, D. & Karikó, K. in Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and Protocols (ed. Rabinovich, P. M.) 29–42 (Humana Press, 2013). · DOI
  18. Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190–2200 (2021). · DOI · Paper page
  19. Tsui, N. B., Ng, E. K. & Lo, Y. D. J. C. C. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647–1653 (2002). · DOI
  20. McKinlay, C. J. et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc. Natl Acad. Sci. USA 114, E448–E456 (2017). · DOI · Paper page
  21. Lee, B. L. & Barton, G. M. Trafficking of endosomal Toll-like receptors. Trends Cell Biol. 24, 360–369 (2014). · DOI
  22. Silverman, R. H. Viral encounters with 2′,5′-oligoadenylate synthetase and RNAse l during the interferon antiviral response. J. Virol. 81, 12720–12729 (2007). · DOI
  23. George, C. X., John, Lijo & Samuel, C. E. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1). J. Interferon Cytokine Res. 34, 437–446 (2014). · DOI
  24. Ross, J. & Sullivan, T. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood 66, 1149–1154 (1985). · DOI · Paper page
  25. Cao, J. et al. High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies. Nat. Commun. 12, 4138 (2021). · DOI · Paper page
  26. Zeng, C. et al. Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Adv. Mater. 32, 2004452 (2020). · DOI · Paper page
  27. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021). · DOI · Paper page
  28. Karikó, K., Muramatsu, H., Keller, J. M. & Weissman, D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20, 948–953 (2012). · DOI · Paper page
  29. Andries, O. et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337–344 (2015). · DOI · Paper page
  30. Baiersdörfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019). · DOI · Paper page
  31. Ramanathan, A., Robb, G. B. & Chan, S.-H. mRNA capping: biological functions and applications. Nucleic Acids Res. 44, 7511–7526 (2016). · DOI
  32. Schlake, T., Thess, A., Thran, M. & Jordan, I. mRNA as novel technology for passive immunotherapy. Cell. Mol. Life Sci. 76, 301–328 (2019). · DOI
  33. Van Dülmen, M., Muthmann, N. & Rentmeister, A. Chemo-enzymatic modification of the 5′ cap maintains translation and increases immunogenic properties of mRNA. Angew. Chem. Int. Ed. 60, 13280–13286 (2021). · DOI
  34. Bollu, A., Peters, A. & Rentmeister, A. Chemo-enzymatic modification of the 5′ cap to study mRNAs. Acc. Chem. Res. 55, 1249–1261 (2022). · DOI
  35. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022). · DOI · Paper page
  36. Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181–12277 (2021). · DOI
  37. Malone, R. W., Felgner, P. L. & Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl Acad. Sci. USA 86, 6077–6081 (1989). · DOI · Paper page
  38. Rejman, J. et al. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 147, 385–391 (2010). · DOI
  39. Kauffman, K. J., Webber, M. J. & Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release 240, 227–234 (2016). · DOI
  40. Cui, S. et al. Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol. Res. 7, 473–479 (2018). · DOI
  41. Xia, Y., Tian, J. & Chen, X. Effect of surface properties on liposomal siRNA delivery. Biomaterials 79, 56–68 (2016). · DOI
  42. Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017). · DOI · Paper page
  43. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603 (1994). · DOI
  44. Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570–1578 (2013). · DOI · Paper page
  45. Zhang, X., Goel, V. & Robbie, G. J. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J. Clin. Pharmacol. 60, 573–585 (2020). · DOI
  46. Richner, J. M. et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170, 273–283.e12 (2017). · DOI · Paper page
  47. Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125.e10 (2017). · DOI · Paper page
  48. Sajid, A. et al. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci. Transl. Med. 13, eabj9827 (2021). · DOI
  49. Mukherjee, A. et al. Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models. Sci. Adv. 6, eabc5911 (2020). · DOI
  50. Szőke, D. et al. Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema. Nat. Commun. 12, 3460 (2021). · DOI
  51. Song, C.-Q. et al. Adenine base editing in an adult mouse model of tyrosinaemia. Nat. Biomed. Eng. 4, 125–130 (2020). · DOI · Paper page
  52. Cheng, X. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 99, 129–137 (2016). · DOI · Paper page
  53. Huang, X. et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. 17, 748–780 (2022). · DOI
  54. Tao, W. et al. siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice. Sci. Transl. Med. 12, eaay1063 (2020). · DOI
  55. Zhu, X. et al. Long-circulating siRNA nanoparticles for validating prohibitin1-targeted non-small cell lung cancer treatment. Proc. Natl Acad. Sci. USA 112, 7779–7784 (2015). · DOI
  56. Kaczmarek, J. C. et al. Systemic delivery of mRNA and DNA to the lung using polymer–lipid nanoparticles. Biomaterials 275, 120966 (2021). · DOI
  57. Lin, Y.-X. et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci. Transl. Med. 13, eaba9772 (2021). · DOI
  58. Xiao, Y. et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat. Commun. 13, 758 (2022). · DOI
  59. Akinc, A., Lynn, D. M., Anderson, D. G. & Langer, R. Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery. J. Am. Chem. Soc. 125, 5316–5323 (2003). · DOI
  60. Green, J. J., Langer, R. & Anderson, D. G. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. 41, 749–759 (2008). · DOI · Paper page
  61. Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020). · DOI
  62. Rui, Y. et al. High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA. Sci. Adv. 8, eabk2855 (2022). · DOI
  63. Benner, N. L. et al. Oligo(serine ester) charge-altering releasable transporters: organocatalytic ring-opening polymerization and their use for in vitro and in vivo mRNA delivery. J. Am. Chem. Soc. 141, 8416–8421 (2019). · DOI
  64. McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M. & Wender, P. A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859–E5866 (2018). · DOI
  65. Haabeth, O. A. W. et al. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc. Natl Acad. Sci. USA 115, E9153–E9161 (2018). · DOI
  66. Haabeth, O. A. et al. An mRNA SARS-CoV-2 vaccine employing charge-altering releasable transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory. ACS Cent. Sci. 7, 1191–1204 (2021). · DOI
  67. Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757–772 (2019). · DOI · Paper page
  68. Li, Z. et al. Exon–intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22, 256–264 (2015). · DOI · Paper page
  69. Pamudurti, N. R. et al. Translation of circRNAs. Mol. Cell 66, 9–21.e27 (2017). · DOI · Paper page
  70. Legnini, I. et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol. Cell 66, 22–37.e9 (2017). · DOI · Paper page
  71. Koch, L. Translated circular RNAs. Nat. Rev. Genet. 18, 272–273 (2017). · DOI
  72. Kauffman, K. et al. Improved immune cell expression with circular RNA (oRNA) in vivo. American Society of Gene & Cell Therapy (ASGCT) Conference 2022 https://www.ornatx.com/wp-content/uploads/2022/05/ASGCT-Poster-221.pdf (2022).
  73. Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01393-0 (2022). · DOI
  74. Shmulevitz, M. & Duncan, R. A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. EMBO J. 19, 902–912 (2000). · DOI
  75. Sun, Y. et al. Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics. Nat. Chem. 14, 274–283 (2022). · DOI
  76. Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019). · DOI · Paper page
  77. Lee, S. M. et al. A systematic study of unsaturation in lipid nanoparticles leads to improved mRNA transfection in vivo. Angew. Chem. Int. Ed. 60, 5848–5853 (2021). · DOI
  78. Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926–9937 (2022). · DOI
  79. Zhang, D. et al. Targeted delivery of mRNA with one-component ionizable amphiphilic Janus dendrimers. J. Am. Chem. Soc. 143, 17975–17982 (2021). · DOI
  80. Zhang, D. et al. One-component multifunctional sequence-defined ionizable amphiphilic Janus dendrimer delivery systems for mRNA. J. Am. Chem. Soc. 143, 12315–12327 (2021). · DOI
  81. Park, J. H. et al. Virus‐mimicking cell membrane‐coated nanoparticles for cytosolic delivery of mRNA. Angew. Chem. Int. Ed. 134, e202113671 (2022). · DOI
  82. Keener, A. B. J. N. How extracellular vesicles can enhance drug delivery. Nature 582, S14–S15 (2020). · DOI
  83. Cully, M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20, 6–7 (2021). · DOI
  84. Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021). · DOI
  85. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021). · DOI · Paper page
  86. Tao, W., & Peppas, N. A. Robotic pills for gastrointestinal-tract-targeted oral mRNA delivery. Matter 5, 775–777 (2022). · DOI
  87. Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2022). · DOI
  88. Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 20, 1578–1589 (2020). · DOI · Paper page
  89. Li, W. et al. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. Nat. Commun. 12, 7264 (2021). · DOI
  90. Zhao, X. et al. Imidazole‐based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew. Chem. Int. Ed. 132, 20258–20264 (2020). · DOI
  91. Ramishetti, S. et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv. Mater. 32, 1906128 (2020). · DOI
  92. Veiga, N. et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 9, 4493 (2018). · DOI · Paper page
  93. Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13, 214–219 (2018). · DOI · Paper page
  94. Su, F.-Y. et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci. Adv. 8, eabm7950 (2022). · DOI
  95. Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNP. Mol. Ther. 29, 3293–3304 (2021). · DOI
  96. Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717–726 (2021). · DOI
  97. Li, J.-Q. et al. Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. Signal Transduct. Target. Ther. 6, 369 (2021). · DOI
  98. Anderluzzi, G. et al. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. J. Control. Release 342, 388–399 (2022). · DOI
  99. Langel, S. N. et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci. Transl. Med. 14, eabn6868 (2022). · DOI
  100. Abramson, A. et al. Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter 5, 975–987 (2022). · DOI
  101. Matinas BioPharma. BioNTech and Matinas BioPharma announce exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines. Matinas BioPharma https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/419/biontech-and-matinas-biopharma-announce-exclusive-research (11 April 2022).
  102. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022). · DOI · Paper page
  103. Tran, E., Longo, D. L. & Urba, W. J. A milestone for CAR T cells. N. Engl. J. Med. 377, 2593–2596 (2017). · DOI
  104. Huang, X. et al. Efficient delivery of mRNA using crosslinked nucleic acid nanogel as a carrier. ACS Mater. Lett. 2, 1509–1515 (2020). · DOI
  105. Zhang, D. et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777–787 (2022). · DOI · Paper page
  106. Huang, X. et al. Intercalation-driven formation of siRNA nanogels for cancer therapy. Nano Lett. 21, 9706–9714 (2021). · DOI
  107. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021). · DOI · Paper page
  108. Maugeri, M. et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat. Commun. 10, 4333 (2019). · DOI · Paper page
  109. Igyártó, B. Z., Jacobsen, S. & Ndeupen, S. Future considerations for the mRNA–lipid nanoparticle vaccine platform. Curr. Opin. Virol. 48, 65–72 (2021). · DOI
  110. Zhang, L. et al. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc. Natl Acad. Sci. USA 118, e2105968118 (2021). · DOI
  111. Aldén, M. et al. Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Curr. Issues Mol. Biol. 44, 1115–1126 (2022). · DOI
  112. Parry, R., Gifford, R. J., Lytras, S., Ray, S. C. & Coin, L. J. M. No evidence of SARS-CoV-2 reverse transcription and integration as the origin of chimeric transcripts in patient tissues. Proc. Natl Acad. Sci. USA 118, e2109066118 (2021). · DOI
  113. Kozma, G. T., Shimizu, T., Ishida, T. & Szebeni, J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Deliv. Rev. 154-155, 163–175 (2020). · DOI · Paper page
  114. Muskula, P. R. & Main, M. L. Safety with echocardiographic contrast agents. Circ. Cardiovasc. Imaging 10, e005459 (2017). · DOI
  115. Corey, K. B. et al. A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies. Ann. Allergy Asthma Immunol. 129, 246–248 (2022). · DOI
  116. Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021). · DOI · Paper page
  117. Zhang, H. et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc. Natl Acad. Sci. USA 118, e2005191118 (2021). · DOI
  118. Paunovska, K. et al. Increased PIP3 activity blocks nanoparticle mRNA delivery. Sci. Adv. 6, eaba5672 (2020). · DOI
  119. McHugh, K. J. et al. Fabrication of fillable microparticles and other complex 3D microstructures. Science 357, 1138–1142 (2017). · DOI
  120. Lu, X. et al. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci. Transl. Med. 12, eaaz6606 (2020). · DOI
  121. Sarmadi, M. et al. Experimental and computational understanding of pulsatile release mechanism from biodegradable core-shell microparticles. Sci. Adv. 8, eabn5315 (2022). · DOI
  122. Rouphael, N. G. et al. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. NPJ Vaccines 6, 89 (2021). · DOI
  123. Xia, D. et al. An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination. Proc. Natl Acad. Sci. USA 118, e2110817118 (2021). · DOI
  124. O’Shea, J., Prausnitz, M. R. & Rouphael, N. Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks. Vaccines 9, 320 (2021). · DOI
  125. Sablad, M. et al. mRNA therapy for ornithine transcarbamylase deficiency. Society for Inherited Metabolic Disorders (SIMD) Conference 2019 https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/April-2019-OTC-Poster-Presented-at-SIMD.pdf?time=1654792975 (2019).
  126. Liu, L. et al. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320, 379–381 (2008). · DOI · Paper page
  127. Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 22, 109–115 (2015). · DOI · Paper page
  128. Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526–1529 (2004). · DOI · Paper page
  129. Züst, R. et al. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12, 137–143 (2011). · DOI · Paper page
  130. Schlee, M. et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31, 25–34 (2009). · DOI
  131. Hornung, V. et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994–997 (2006). · DOI · Paper page
  132. Cobb, M. Who discovered messenger RNA? Curr. Biol. 25, R526–R532 (2015). · DOI
  133. Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55, 1397–1400 (1995).

Cited by

Sorted by citations

Metadata

Authors
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W.
Affiliations
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • Karolinska Institutet (SE)
Corresponding author
  • Cao, Yihai
  • Tao, Wei
ORCID
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2022-11
Volume
28
Issue
11
Pages
2273-2287
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-022-02061-1
OpenAlex
W4308834995
Cited by
511
References
77
Citations by year
2026: 99 · 2025: 131 · 2024: 157 · 2023: 122 · 2022: 2
FWCI
10.73
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Heart Association (2018A004190)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
mRNA therapeutics, mRNA vaccines, COVID-19 vaccines, mRNA stability, immunogenicity, in vivo delivery, clinical translation
MeSH terms
COVID-19, Humans, Proteins, RNA, Messenger, Nanomedicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review